EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis

Yayoi Natsume-Kitatani iD, Mari N Itoh, Yoshito Takeda, Masataka Kuroda, Haruhiko Hirata, Kotaro Miyake, Takayuki Shiroyama, Yuya Shirai, Yoshimi Noda, Yuichi Adachi, Takatoshi Enomoto, Saori Amiya und 21 weitere

Briefings in Bioinformatics · 01.03.2026 · 27 (2)

DOI: 10.1093/bib/bbag153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 14.04.2026. Verfasst von Yayoi Natsume-Kitatani und 32 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Bioinformatics, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health…. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labor and Welfare, Cabinet Office of the Japan Government for the Public/Private R&D Investment Strategic Expansion Program, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is an intractable lung disease that belongs to idiopathic interstitial pneumonia (IIP) with limited therapeutic options. Conventional patient stratification approaches often fail to integrate diverse data modalities, particularly heterogeneous electronic medical records (EMR) containing mixed discrete and continuous values, with omics data, or fail to extract the interpretable many-to-many relationships crucial for precision medicine. We introduce subset binding (SB), a novel unsupervised algorithm that extends fuzzy association rule mining to robustly integrate heterogeneous clinical data (EMR) and omics data. This framework is uniquely designed to identify clinically meaningful patient subgroup patterns and discover associated molecular signatures based on observable symptoms rather than relying on ambiguous conventional diagnostic categories, such as IIPs. Applying SB to a dataset including 602 samples (from 403 IIPs including IPF patients and 39 healthy controls), we successfully identified 20 proteins linked with key IPF clinical features. Network-based pathway analysis nominated tyrosine kinases as critical drug target candidates, leading to the proposal of ponatinib, a multi-kinase inhibitor, as a candidate therapeutic. Functional validation using a TGF-β-induced epithelial-mesenchymal transition (EMT) model confirmed ponatinib’s ability to at least partially suppress TGF-β-induced EMT. This inhibitory effect is consistent with the anti-fibrotic mechanism of the existing IPF drug, nintedanib, and reinforces prior evidence supporting ponatinib’s anti-fibrotic property. This study demonstrates that SB enables transparent, reproducible, and robust, molecularly defined patient stratification from multimodal patient data. By establishing a data-driven framework that focuses on observation-based rules, this work lays the critical foundation for future prognostic validation and tailored treatment strategies, offering clinically actionable insights and therapeutic discovery in diagnostically ambiguous diseases like IPF, with ponatinib emerging as a compelling repurposing candidate. Significance statement Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited therapeutic options. IPF is classified as idiopathic interstitial pneumonia (IIP), but distinguishing it from other similar diseases in IIP is not straightforward. The ambiguities in distinguishing IPF from other IIPs necessitate the identification of molecules associated with specific clinical features, rather than relying on solely on diagnosis. Existing methods for multi-omics data analysis often fail to effectively integrate heterogeneous data – such as EMR (containing mixed discrete and continuous values) and omics – or to extract many-to-many molecular-phenotypic relationships. We developed subset binding (SB), a novel, interpretable unsupervised machine learning method to specifically address these technical limitations by integrating EMR and omics data. Our approach successfully detected proteins in serum extracellular vesicles associated with IPF-related features, highlighted several tyrosine kinases as potential drug targets, and proposed the multi-kinase inhibitor ponatinib as a compelling candidate for drug repurposing. This data-driven framework establishes a scalable and interpretable foundation for biomarker and drug target discovery for intractable diseases whose mechanisms are not fully understood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisDrug DiscoveryHumansAlgorithmsEpithelial-Mesenchymal TransitionPyridazinesImidazolesProtein Kinase Inhibitors

Stichwörter der Autor:innen

IPFdrug target discoverypatient stratification

Substanzen

PyridazinesponatinibImidazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Laboratory of Bioinformatics, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition; 3-17 Senrioka-shinmachi, Settsu, Osaka 567-0085, Japan.
  • Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
  • Institute for Protein Research, the University of Osaka, 3-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
  • Graduate School of Pharmaceutical Sciences, the University of Osaka, 1-10 Yamada-oka, Suita, Osaka 565-0871, Japan.
  • Department of Respiratory Medicine and Clinical Immunology, the University of Osaka Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
  • Discovery Technology Laboratories, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033, Japan.

ORCID-Profile: Yayoi Natsume-Kitatani, Yosui Nojima, Kenji Mizuguchi, Atsushi Kumanogoh

Förderung

  • Ministry of Health, Labor and Welfare
  • Cabinet Office of the Japan Government for the Public/Private R&D Investment Strategic Expansion Program
  • Japan Society for the Promotion of Science

Zitieren

APA

Natsume-Kitatani, Y., Itoh, M. N., Takeda, Y., Kuroda, M., Hirata, H., Miyake, K., Shiroyama, T., Shirai, Y., Noda, Y., Adachi, Y., Enomoto, T., Amiya, S., Adachi, J., Narumi, R., Muraoka, S., Tomonaga, T., Kurohashi, S., Cheng, F., Tanaka, R., …, & Ueda, N. (2026). Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis. Briefings in Bioinformatics, 27(2). https://doi.org/10.1093/bib/bbag153

Vancouver

Natsume-Kitatani Y, Itoh MN, Takeda Y, Kuroda M, Hirata H, Miyake K, et al. Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis. Briefings in Bioinformatics. 2026;27(2). doi:10.1093/bib/bbag153

BibTeX
@article{NatsumeKitatani2026,
  author = {Natsume-Kitatani, Yayoi and Itoh, Mari N and Takeda, Yoshito and Kuroda, Masataka and Hirata, Haruhiko and Miyake, Kotaro and Shiroyama, Takayuki and Shirai, Yuya and Noda, Yoshimi and Adachi, Yuichi and Enomoto, Takatoshi and Amiya, Saori and Adachi, Jun and Narumi, Ryohei and Muraoka, Satoshi and Tomonaga, Takeshi and Kurohashi, Sadao and Cheng, Fei and Tanaka, Ribeka and Yada, Shuntaro and Aramaki, Eiji and Wakamiya, Shoko and Chen, Yi-An and Fukagawa, Akiko and Higuchi, Chihiro and Nojima, Yosui and Fujiwara, Takeshi and Nagao, Chioko and Takeda, Toshihiro and Matsumura, Yasushi and Mizuguchi, Kenji and Kumanogoh, Atsushi and Ueda, Naonori},
  title = {Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis},
  journal = {Briefings in Bioinformatics},
  year = {2026},
  volume = {27},
  number = {2},
  doi = {10.1093/bib/bbag153}
}
Kostenlos starten →